Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

In This Article:

Biofrontera Inc.
Biofrontera Inc.

Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025

WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update.

Highlights from the first quarter of 2025 and subsequent weeks included the following:

  • Total revenues for the first quarter of 2025 were $8.6 million, a 9% increase from the same period of the prior year.

  • Cash and cash equivalents were $1.8 million as of March 31, 2025, compared with $5.9 million on December 31, 2024.

  • Announced the enrollment of the final patient in the Phase 3 clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of mild to moderate actinic keratoses on the extremities, neck and trunk.

  • Achieved a key milestone in the Phase 3 study of the use of Ameluz® and RhodoLED® photodynamic therapy (“PDT”) in the treatment of sBCC (ALA-BCC-CT013), with the last patient completing the 1-year follow-up visit in December 2024.

  • Received patent approval for a revised formulation of Ameluz® which extends protection for the treatment through to December 2043.

  • Completed patient enrollment in phase 2b study of Ameluz® Topical Gel, 10% for the treatment of moderate to severe acne vulgaris.

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., stated, "The beginning of 2025 has been a very encouraging and rewarding period for us, as we have improved our revenues by 9%. We continue to see current customers reordering as well as new medical offices coming on board and placing their initial orders of Ameluz®, illustrating the strength of our products and the success of our sales and marketing efforts. As part of our combination therapy, we also sold a good mix of the two differently-sized BF-RhodoLED® lamps.”

"The enrollment of the final patient in the Phase 3 clinical trial evaluating Ameluz® for the treatment of mild to moderate actinic keratoses on the extremities, neck and trunk is something that we are excited about. Additionally, our past investments in PDT allow us to strategically plan and establish partnerships with dermatologists to future expansions of our label to the treatment of a cutaneous malignancy or moderate to severe acne,” concluded Mr. Luebbert.

First Quarter Financial Results

Total revenues for the three months ended March 31, 2025 were $8.6 million, an increase of $0.7 million, or 8.7% as compared to the three months ended March 31, 2024. The increase was driven by a $0.5 million increase in Ameluz® sales due to an increased unit price and the launch of our RhodoLED® XL Lamp, which resulted in sales of RhodoLED®XL lamps of $0.2 million.